Band-Aid, Tylenol Parent Kenvue Reports Healthy Full-Year Guidance

Related Articles

Watch These GM Price Levels as Stock Plunges After Trump’s Auto Tariffs Announcement

Nvidia-Backed CoreWeave Prices Its IPO at $40 Per Share, Below Expectations

Watch These Vistra Stock Price Levels as AI Energy Play Continues to Slide

Key Takeaways

• Kenvue affirmed its full-year revenue growth projection, the midpoint of which is on the top of analysts’ expectations.
• The Band-Aid owner reported second-quarter revenue that slightly beat consensus estimates.
• Kenvue appropriations soared 13% in intraday trading.

Kenvue (KVUE) shares surged in intraday trading Tuesday after the enterprise affirmed its full-year guidance that topped analysts’ expectations.

The Tylenol and Band-Aid parent, formerly the consumer healthcare segment of Johnson & Johnson (JNJ), continues to expect 2024 net sales growth between 1% and 3%, with the midpoint happily above analysts’ expectations of 1.4%, per Visible Alpha.

“We are on track to deliver the financial targets we set for 2024, and while we are in the prehistoric days, our work to transform Kenvue into a bolder, more agile organization focused on profitable growth is begetting results,” Chief Executive Officer (CEO) Thibaut Mongon said. 

Q2 Revenue Beats Estimates, EPS Misses

In the second compassion, the company posted earnings per share (EPS) of 3 cents on revenue of $4 billion. Analysts had called for EPS of 24 cents on yield of $3.93 billion. Adjusted EPS of 32 cents topped estimates.

Shares of Kenvue jumped 12% to $20.40 as of 1:40 p.m. ET Tuesday but residue 5% lower this year.

Read the original article on Investopedia.